CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

Company Overview

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms. Its programs are designed to support allogeneic, or donor-derived, cell therapies and may incorporate genetic engineering and other methods intended to improve the cells’ ability to target cancer.

The company conducts its research and development activities in Singapore and has worked with academic and clinical research institutions in the country. CytoMed’s candidates remain investigational, and their safety and effectiveness depend on the results of ongoing and future clinical development.

Key Stats

• Today's Range: $0.91 to $0.91
• 50-Day Range: $0.78 to $1.03
• 52-Week Range: $0.68 to $3.68
• Volume: 332 shs
• Average Volume: 230,340 shs
• Market Capitalization: $10.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.16
• Consensus Rating: Hold

CytoMed Therapeutics Stock Analysis - MarketRank™

CytoMed Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 723rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

CytoMed Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

CytoMed Therapeutics has a consensus price target of $4.16, representing about 357.1% upside from its current price of $0.91.

Amount of Analyst Coverage

CytoMed Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

CytoMed Therapeutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of CytoMed Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytoMed Therapeutics has a short interest ratio ("days to cover") of 0.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CytoMed Therapeutics has recently increased by 51.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoMed Therapeutics does not currently pay a dividend.

Dividend Growth

CytoMed Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.04% of the stock of CytoMed Therapeutics is held by institutions.

Company Calendar

• Today: 9/24/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GDTC
• CIK: 1873093
• Web: w2.cytomed.sg
• Phone: 65-6250-7738
• Fax: N/A
• Employees: 42
• Year Founded: 2018

Price Target and Rating

• Average Price Target for CytoMed Therapeutics: $4.16
• High Price Target: $4.16
• Low Price Target: $4.16
• Potential Upside/Downside: +381.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 5.17
• Quick Ratio: 5.17

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 40.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 1.92

Miscellaneous

• Outstanding Shares: 11,830,000
• Free Float: N/A
• Market Cap: $10.22 million
• Optionable: Not Optionable
• Beta: 0.04